Clinton Group’s DexCom DXCM Stock Holding History

Clinton Group’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-8,468	Closed	-$201K	–	245
2018 Q2	$201K	Buy	+8,468	New	+$180K	0.03%	333
2017 Q3	–	Sell	-34,948	Closed	-$639K	–	438
2017 Q2	$639K	Buy	+34,948	New	+$645K	0.07%	349

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Clinton Group's DXCM Position: Q3 2018 in Review

Clinton Group sold out of DexCom (DXCM) in Q3 2018, closing a stake of 8,468 shares — an estimated $201K sold.

Clinton Group first reported a position in DXCM in Q2 2017 and held it in 2 quarters. The position peaked at $639K in Q2 2017. 363 funds tracked by Wall St. Rank hold DXCM as of Q3 2018.

Clinton Group reported no remaining DexCom position as of Q3 2018 after selling out during the quarter.
Clinton Group sold 8,468 DexCom shares in Q3 2018, an estimated $201K.
Clinton Group first reported a position in DexCom in Q2 2017 and held it in 2 quarters.
Clinton Group's DexCom position peaked at $639K in Q2 2017.
363 funds tracked by Wall St. Rank held DexCom as of Q3 2018.

Based on Clinton Group's 13F filing for Q3 2018, filed 10 Oct 2018.